Analyst consensus rating
Harmony Biosciences Holdings Analyst Rating: Buy
Direct answer
Harmony Biosciences Holdings's consensus rating is Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $47.36.
Forecast evidence checked September 16, 2026.
Get free Harmony Biosciences Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $42.17
- Average price target
- $47.36
- High price target
- $70.00
- Low price target
- $30.00
- Low target gap
- -28.9%
- Target upside
- +12.3%
- High target gap
- +66%
- Target range width
- 94.9%
- Consensus rating
- Buy
- Analysts
- 11
- Evidence date
- September 16, 2026
- Valid through
- September 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Harmony Biosciences Holdings?
Harmony Biosciences Holdings has a verified Buy consensus. The same dataset has an average price target of $47.36.
How far are Harmony Biosciences Holdings's low and high targets from the recorded price?
The low target implies -28.9%, while the high target implies +66%.
How many analysts are included in Harmony Biosciences Holdings's consensus?
The verified consensus includes 11 analysts.
How is Harmony Biosciences Holdings's target upside or downside calculated?
The average target of $47.36 is divided by the recorded price of $42.17, then one is subtracted to produce +12.3%. This does not guarantee a future return.
When was Harmony Biosciences Holdings's analyst forecast verified?
The data was verified on 2026-09-16. The dataset is valid through 2026-09-23.